The epidermal growth factor receptor mediates radioresistance.
about
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancersTargeting angiogenesis in gynecologic cancersLung cancer cells that survive ionizing radiation show increased integrin α2β1- and EGFR-dependent invasivenessRadiation-induced immune responses: mechanisms and therapeutic perspectivesAfatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectivesBrain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival.Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review).Identification of new peptide ligands for epidermal growth factor receptor using phage display and computationally modeling their mode of binding.The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.Overview of radiation therapy for treating rectal cancer.EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324.The role of capecitabine in locally advanced rectal cancer treatment: an update.Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumoursPhase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.Simvastatin Enhances the Effects of Radiotherapy and Cetuximab on a Cell Line (FaDu) Derived from a Squamous Cell Carcinoma of Head and NeckRectal cancer treatment: improving the picture.Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors.EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastasesNeoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.Investigation of radiation-induced transcriptome profile of radioresistant non-small cell lung cancer A549 cells using RNA-seqVandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity.Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib.Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324EGFRvIII mediates hepatocellular carcinoma cell invasion by promoting S100 calcium binding protein A11 expression.Emerging drugs to treat squamous cell carcinomas of the head and neck.Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair.Epidermal growth factor receptor expression in canine transitional cell carcinomaTherapeutic advances in women's cancersOutcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.Xenograft assessment of predictive biomarkers for standard head and neck cancer therapiesEGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.Efficient blockade of Akt signaling is a determinant factor to overcome resistance to matuzumab.The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1αThe current state of targeted agents in rectal cancer.Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytomaCorrelation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma.
P2860
Q24611483-5B8909AB-F1D4-4711-BCE3-08847FF328C7Q26824766-C5B73956-C6F1-4692-AA71-0E02435C1414Q27310015-1ED32C33-5A3B-401B-82C7-2D370A5A215BQ28080006-2C03EF04-7185-4669-BD0E-63466C2DBDA0Q33591405-1E703447-3FDE-482C-AFB6-513E9F998806Q33612305-06C060A1-2E93-4DA8-84CA-1536B24201C2Q33648808-4ADB8D5B-A923-4B48-9434-3C9450CC601BQ33822929-B18230BE-463D-4337-AFA7-F0C3451FE38DQ33831950-5B6B11D5-C84A-4102-948F-41585427C0E0Q33933054-6D34E6CA-12B1-4D02-A3F4-83F1E06A5872Q34089704-5348B6B3-E784-442C-9915-CCF5AE7AA0E0Q34103230-5AB5A5F8-FA50-48C2-8635-87497B9009FAQ34136267-E020696B-3A5D-45B7-B470-8959B1D3DF08Q34216725-2BF1967E-C780-4BA9-AB5C-1AA4198A7352Q34276823-BDDD746A-5E71-406C-BDA7-75AF877A3E99Q34283737-79A8CA69-50F2-448E-8DB4-C736B45A488BQ34287666-143C166B-450E-41B4-820F-F81410A87894Q34369305-70C26CEA-C965-45D1-B7AB-C8CA51694408Q34382761-81719B53-50D7-471A-8266-6FA503EBB3D0Q34446069-3B157669-8FCE-40FA-B2CF-768361842330Q34461771-D3E2FD34-BB27-4BAB-ABDA-F1B32C48C1ACQ34471583-EE64D8CE-5439-4C77-BA81-70E62E32CD49Q34637764-71F770C3-0426-4E5B-9559-C489C18A01A4Q34781075-29D96F3D-CE90-408D-82CD-090AAB29D6C8Q34887667-985D26CD-0F56-4090-89AC-B6B52A999976Q35009672-669560FF-011E-44DA-A6F8-8BAE8B95EB14Q35023433-B2FDA9B3-3582-44A5-9636-4D17CE042EDBQ35078031-F7679F1E-4D33-4720-861E-D75F88BB7520Q35098322-0689D55C-763F-4561-AE89-FEC53D643892Q35142705-5D84FBFE-6FB6-4424-8C82-7CDF21DD1C6EQ35147084-913E3BAD-7040-4D92-8DC3-E7279ACB6301Q35418973-EA58EA2B-9E51-450D-829D-D3B853AD3892Q35584972-20413238-6246-45B4-B34F-C056ACCBFFFFQ35602135-8AAA45D2-22CA-4F8D-A74D-72C2CB36E033Q35800614-086BCEEE-2A44-48F1-A780-7774BA11D79FQ35808930-6A6E3F57-D739-4EBB-AFF6-CD419D35D9FBQ35992051-DEF14F2C-6EBC-419D-8BC3-D70566D8154FQ35996651-C0DFC3CA-E84F-4D0E-8764-869EC27C4680Q36033783-EA67E40C-41F5-43DB-8150-F514AD480840Q36061130-684D012B-9988-49A2-8F6E-325614605517
P2860
The epidermal growth factor receptor mediates radioresistance.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
The epidermal growth factor receptor mediates radioresistance.
@en
The epidermal growth factor receptor mediates radioresistance.
@nl
type
label
The epidermal growth factor receptor mediates radioresistance.
@en
The epidermal growth factor receptor mediates radioresistance.
@nl
prefLabel
The epidermal growth factor receptor mediates radioresistance.
@en
The epidermal growth factor receptor mediates radioresistance.
@nl
P2093
P1476
The epidermal growth factor receptor mediates radioresistance.
@en
P2093
P304
P356
10.1016/S0360-3016(03)00511-X
P407
P577
2003-09-01T00:00:00Z